Vise Technologies Inc. Makes New Investment in Hims & Hers Health, Inc. $HIMS

Vise Technologies Inc. purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,947 shares of the company’s stock, valued at approximately $247,000.

Other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC increased its stake in Hims & Hers Health by 15.7% during the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock valued at $49,000 after purchasing an additional 227 shares in the last quarter. Bessemer Group Inc. increased its position in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after acquiring an additional 312 shares in the last quarter. True Vision MN LLC raised its holdings in Hims & Hers Health by 3.6% in the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock worth $467,000 after acquiring an additional 328 shares during the last quarter. Signaturefd LLC lifted its position in Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock valued at $76,000 after acquiring an additional 388 shares in the last quarter. Finally, WealthPlan Investment Management LLC lifted its position in Hims & Hers Health by 2.6% in the 2nd quarter. WealthPlan Investment Management LLC now owns 16,404 shares of the company’s stock valued at $818,000 after acquiring an additional 410 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Canaccord Genuity Group restated a “buy” rating and issued a $68.00 price target on shares of Hims & Hers Health in a research note on Friday, September 12th. Zacks Research lowered Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. BTIG Research reissued a “buy” rating and set a $85.00 price objective on shares of Hims & Hers Health in a report on Tuesday, November 4th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Tuesday, November 11th. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health has a consensus rating of “Reduce” and an average target price of $45.27.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock in a transaction on Monday, September 15th. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the transaction, the chief financial officer directly owned 128,984 shares in the company, valued at approximately $7,139,264.40. The trade was a 52.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Chi sold 13,749 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $694,324.50. Following the transaction, the insider directly owned 297,139 shares in the company, valued at $15,005,519.50. This represents a 4.42% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 584,209 shares of company stock valued at $31,837,916. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Price Performance

NYSE HIMS opened at $35.63 on Tuesday. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The firm has a market capitalization of $8.11 billion, a P/E ratio of 65.98, a PEG ratio of 7.36 and a beta of 2.20. The company has a 50-day moving average price of $50.35 and a 200-day moving average price of $51.45. Hims & Hers Health, Inc. has a 52 week low of $19.29 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. During the same quarter last year, the firm posted $0.32 earnings per share. The business’s quarterly revenue was up 49.2% compared to the same quarter last year. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its board has authorized a stock buyback plan on Monday, November 17th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to purchase up to 3% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.